1. Home
  2. DVAX vs SEMR Comparison

DVAX vs SEMR Comparison

Compare DVAX & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • SEMR
  • Stock Information
  • Founded
  • DVAX 1996
  • SEMR 2008
  • Country
  • DVAX United States
  • SEMR United States
  • Employees
  • DVAX N/A
  • SEMR N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • SEMR EDP Services
  • Sector
  • DVAX Health Care
  • SEMR Technology
  • Exchange
  • DVAX Nasdaq
  • SEMR Nasdaq
  • Market Cap
  • DVAX 1.3B
  • SEMR 1.3B
  • IPO Year
  • DVAX 2004
  • SEMR 2021
  • Fundamental
  • Price
  • DVAX $10.26
  • SEMR $7.86
  • Analyst Decision
  • DVAX Buy
  • SEMR Buy
  • Analyst Count
  • DVAX 4
  • SEMR 8
  • Target Price
  • DVAX $26.50
  • SEMR $14.88
  • AVG Volume (30 Days)
  • DVAX 1.8M
  • SEMR 1.5M
  • Earning Date
  • DVAX 08-07-2025
  • SEMR 08-04-2025
  • Dividend Yield
  • DVAX N/A
  • SEMR N/A
  • EPS Growth
  • DVAX N/A
  • SEMR N/A
  • EPS
  • DVAX N/A
  • SEMR N/A
  • Revenue
  • DVAX $316,268,000.00
  • SEMR $413,962,000.00
  • Revenue This Year
  • DVAX $23.23
  • SEMR $20.28
  • Revenue Next Year
  • DVAX $16.57
  • SEMR $16.41
  • P/E Ratio
  • DVAX N/A
  • SEMR N/A
  • Revenue Growth
  • DVAX 26.66
  • SEMR 22.16
  • 52 Week Low
  • DVAX $9.22
  • SEMR $7.01
  • 52 Week High
  • DVAX $14.63
  • SEMR $18.74
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 42.08
  • SEMR 46.18
  • Support Level
  • DVAX $10.27
  • SEMR $7.63
  • Resistance Level
  • DVAX $11.45
  • SEMR $8.01
  • Average True Range (ATR)
  • DVAX 0.45
  • SEMR 0.27
  • MACD
  • DVAX -0.06
  • SEMR 0.07
  • Stochastic Oscillator
  • DVAX 18.18
  • SEMR 84.50

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.

Share on Social Networks: